Article

AAO squeezes "fresh ideas" into annual

Author(s):

Susanne Medeiros

The focus of the American Academy of Ophthalmology's (AAO) annual meeting in Anaheim this November can be summed up in one word: fresh. As always, the annual meeting and subspecialty day meetings will provide the latest clinical updates and practical tools that attendees have come to expect, but with a fresh focus on their needs on everything from offerings to scheduling.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Krystal Biotech doses first patient in phase 3 trial IOLITE
June 27th 2025

Krystal Biotech doses first patient in phase 3 trial IOLITE

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%
June 26th 2025

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

© 2025 MJH Life Sciences

All rights reserved.